J&J meets Q4 ex­pec­ta­tions with $21.4B in sales as it stares down patent cliff

John­son & John­son met its fore­casts for the fourth quar­ter of 2023, re­port­ing a 7.3% sales growth to $21.4 bil­lion and full-year re­port­ed sales in­crease of 6.5% to $85.2 bil­lion for the year.

J&J al­so re­con­firmed its 2024 op­er­a­tional sales growth pre­dic­tion of 5% to 6% and said it ex­pects sales to be high­er in the first half of the year com­pared to the sec­ond.

In Q4 of 2023, US sales brought in around $12 bil­lion (a jump from $10 bil­lion in 2022) and $9.3 bil­lion in­ter­na­tion­al­ly for a to­tal of $21.3 bil­lion. Its in­no­v­a­tive med­i­cine port­fo­lio in­creased by 7.2% world­wide, led by on­col­o­gy prod­ucts, in­clud­ing Er­lea­da and Carvyk­ti, as well as Ste­lara in im­munol­o­gy.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER